5
Juvenile Idiopathic Arthritis Uveitis Author: Manolette R Roque, MD, MBA; Chief Editor: Hampton Roy Sr, MD more... Updated: Jun 19, 2012 Background Approximately 6% of all cases of uveitis arise in children. [1] The most frequent cause of chronic intraocular inflammation among children is juvenile idiopathic arthritis (JIA)associated uveitis. [2] A unifying classification, juvenile idiopathic arthritis (JIA), encompassing juvenile chronic arthritis and juvenile rheumatoid arthritis (JRA), has been developed by consensus. Acute anterior uveitis with hypopyon in a child. Courtesy of Manolette Roque, MD, Ophthalmic Consultants Philippines Co, EYE REPUBLIC Ophthalmology Clinic. Chronic iridocyclitis occurs in 1020% of all patients with JIA. [3, 4, 5, 6] Chronic uveitis characteristically is asymptomatic in children with JIA, leading to insidious but progressive morbidity and possible blindness. The involved eyes often are white and quiet appearing, yet 3040% of patients with JIAassociated uveitis experience severe loss of vision as a consequence of their condition. JIA, as defined by the American Rheumatism Association (ARA), is the presence of arthritis (chronic, seronegative, and peripheral) before age 16 years, of at least 3 months duration, when other causes have been excluded. It is classified by 1 of 3 types of onset. [7] Oligoarticular (pauciarticular) onset JIA (4060%) is common in girls (5:1). Peak age of onset is at age 2 years. Four or fewer joints are involved during the first 6 months of the disease (often asymmetric). Oligoarticular onset commonly involves the knees and, less frequently, the ankles and wrists. The arthritis may be evanescent, rarely destructive, and radiologically insignificant. Approximately 75% of these patients test positive for antinuclear antibody (ANA). This mode of onset rarely is associated with systemic signs. A high risk for uveitis exists. [8] Polyarticular onset JIA (2040%) is common in girls (3:1). Peak age of onset is at age 3 years. It involves 5 or more joints during the first 6 months of the disease. Polyarticular onset JIA commonly involves the small joints of the hand and, less frequently, the larger joints of the knee, ankle, or wrist. Asymmetric arthritis may be acute or chronic and may be destructive in 15% of patients. Immunoglobulin M (IgM) rheumatoid factor (RF) is present in 10% of children with this JIA subgroup. It is associated with subcutaneous nodules, erosions, and a poor prognosis. Approximately 40% of these patients test positive for ANA. Systemic symptoms, including anorexia, anemia, and growth retardation, are moderate. An intermediate risk for uveitis exists. Systemic onset JIA (1020%) is equal frequency in boys and girls and can appear at any age. Symmetric polyarthritis is present and may be destructive in 25% of patients. Hands, wrists, feet, ankles, elbows, knees, hips, shoulders, cervical spine, and jaw may be involved. ANA is positive in only 10% of the patients. Systemic onset is associated with fever (high in evening and normal in morning), macular rash, leukocytosis, lymphadenopathy, and hepatomegaly. Pericarditis, pleuritis, splenomegaly, and abdominal pain less commonly are observed. A low risk for uveitis exists. Pathophysiology The cause of uveitis and arthritis in JIA remains unknown. [9] Akin to many other autoimmune diseases, the target antigen is unidentified. Immune reactions to ocular antigens (S antigen or iris antigen) have been studied; however, their actual role (active or passive) is unknown. The course of the disease may be short and limited or progressive and severe. Epidemiology Frequency United States JIA has an estimated prevalence of about 113 cases per 100,000 children. It is estimated that JIA afflicts 60,000 70,000 children, but only a minority develop eye disease. Incidence of eye disease in the JIA population is uncertain, but it is believed to be around 10%. [7] Mortality/Morbidity Morbidity in JIAassociated uveitis may result either from lack of treatment or from overzealous treatment. Mortality may result from the latter.

Juvenile Idiopathic Arthritis Uveitis

Embed Size (px)

DESCRIPTION

jia uveitis

Citation preview

  • 3/25/2015 JuvenileIdiopathicArthritisUveitis

    http://emedicine.medscape.com/article/1209891overview 1/5

    JuvenileIdiopathicArthritisUveitisAuthor:ManoletteRRoque,MD,MBAChiefEditor:HamptonRoySr,MDmore...

    Updated:Jun19,2012

    Background

    Approximately6%ofallcasesofuveitisariseinchildren.[1]Themostfrequentcauseofchronicintraocularinflammationamongchildrenisjuvenileidiopathicarthritis(JIA)associateduveitis.[2]Aunifyingclassification,juvenileidiopathicarthritis(JIA),encompassingjuvenilechronicarthritisandjuvenilerheumatoidarthritis(JRA),hasbeendevelopedbyconsensus.

    Acuteanterioruveitiswithhypopyoninachild.CourtesyofManoletteRoque,MD,OphthalmicConsultantsPhilippinesCo,EYEREPUBLICOphthalmologyClinic.

    Chroniciridocyclitisoccursin1020%ofallpatientswithJIA.[3,4,5,6]ChronicuveitischaracteristicallyisasymptomaticinchildrenwithJIA,leadingtoinsidiousbutprogressivemorbidityandpossibleblindness.Theinvolvedeyesoftenarewhiteandquietappearing,yet3040%ofpatientswithJIAassociateduveitisexperienceseverelossofvisionasaconsequenceoftheircondition.

    JIA,asdefinedbytheAmericanRheumatismAssociation(ARA),isthepresenceofarthritis(chronic,seronegative,andperipheral)beforeage16years,ofatleast3monthsduration,whenothercauseshavebeenexcluded.Itisclassifiedby1of3typesofonset.[7]

    Oligoarticular(pauciarticular)onsetJIA(4060%)iscommoningirls(5:1).Peakageofonsetisatage2years.Fourorfewerjointsareinvolvedduringthefirst6monthsofthedisease(oftenasymmetric).Oligoarticularonsetcommonlyinvolvesthekneesand,lessfrequently,theanklesandwrists.Thearthritismaybeevanescent,rarelydestructive,andradiologicallyinsignificant.Approximately75%ofthesepatientstestpositiveforantinuclearantibody(ANA).Thismodeofonsetrarelyisassociatedwithsystemicsigns.Ahighriskforuveitisexists.[8]

    PolyarticularonsetJIA(2040%)iscommoningirls(3:1).Peakageofonsetisatage3years.Itinvolves5ormorejointsduringthefirst6monthsofthedisease.PolyarticularonsetJIAcommonlyinvolvesthesmalljointsofthehandand,lessfrequently,thelargerjointsoftheknee,ankle,orwrist.Asymmetricarthritismaybeacuteorchronicandmaybedestructivein15%ofpatients.ImmunoglobulinM(IgM)rheumatoidfactor(RF)ispresentin10%ofchildrenwiththisJIAsubgroup.Itisassociatedwithsubcutaneousnodules,erosions,andapoorprognosis.Approximately40%ofthesepatientstestpositiveforANA.Systemicsymptoms,includinganorexia,anemia,andgrowthretardation,aremoderate.Anintermediateriskforuveitisexists.

    SystemiconsetJIA(1020%)isequalfrequencyinboysandgirlsandcanappearatanyage.Symmetricpolyarthritisispresentandmaybedestructivein25%ofpatients.Hands,wrists,feet,ankles,elbows,knees,hips,shoulders,cervicalspine,andjawmaybeinvolved.ANAispositiveinonly10%ofthepatients.Systemiconsetisassociatedwithfever(highineveningandnormalinmorning),macularrash,leukocytosis,lymphadenopathy,andhepatomegaly.Pericarditis,pleuritis,splenomegaly,andabdominalpainlesscommonlyareobserved.Alowriskforuveitisexists.

    Pathophysiology

    ThecauseofuveitisandarthritisinJIAremainsunknown.[9]Akintomanyotherautoimmunediseases,thetargetantigenisunidentified.Immunereactionstoocularantigens(Santigenoririsantigen)havebeenstudiedhowever,theiractualrole(activeorpassive)isunknown.Thecourseofthediseasemaybeshortandlimitedorprogressiveandsevere.

    Epidemiology

    Frequency

    UnitedStates

    JIAhasanestimatedprevalenceofabout113casesper100,000children.ItisestimatedthatJIAafflicts60,00070,000children,butonlyaminoritydevelopeyedisease.IncidenceofeyediseaseintheJIApopulationisuncertain,butitisbelievedtobearound10%.[7]

    Mortality/Morbidity

    MorbidityinJIAassociateduveitismayresulteitherfromlackoftreatmentorfromoverzealoustreatment.Mortalitymayresultfromthelatter.

  • 3/25/2015 JuvenileIdiopathicArthritisUveitis

    http://emedicine.medscape.com/article/1209891overview 2/5

    Race

    Noknownracialpredilectionexists.

    Sex

    Astrongpredilectionexistsforgirls.Thegirltoboyratiois4:1.

    Age

    JIAisachildhooddisease.

    Bydefinition,JIAoccursinchildrenyoungerthanage16years.Inviewofthefactthattheoculardiseasecanfollowthesystemicdiseasebynumerousyears,alotofpatientsarewellbeyondtheirteenswhentheyareexaminedandtreatedforuveitis.[10]

    ContributorInformationandDisclosuresAuthorManoletteRRoque,MD,MBAGeneralManager,FullPartner,OphthalmicConsultantsPhilippinesCo.PresidentandCEO,ChiefRefractiveSurgeon,EYEREPUBLICOphthalmologyClinicSectionChief,OcularImmunologyandUveitis,DepartmentofOphthalmology,AsianHospitalandMedicalCenterSectionChief,OcularImmunologyandUveitis,InternationalEyeInstitute,StLuke'sMedicalCenterGlobalCitySeniorEyeSurgeon,TheLASIKSurgeryClinicDirector,AMCEyeCenter,AlabangMedicalCenterPresident,PhilippineOcularInflammationSociety

    ManoletteRRoque,MD,MBAisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmicExecutives,AmericanAcademyofOphthalmology,AmericanSocietyofCataractandRefractiveSurgery,AmericanSocietyofOphthalmicAdministrators,AmericanUveitisSociety,InternationalOcularInflammationSociety,PhilippineMedicalAssociation,PhilippineOcularInflammationSociety,andPhilippineSocietyofCataractandRefractiveSurgery

    Disclosure:Nothingtodisclose.

    Coauthor(s)BarbaraLRoque,MDFullPartner,OphthalmicConsultantsPhilippinesCoServiceChief,PediatricOphthalmologyandStrabismus,DepartmentofOphthalmology,AsianHospitalandMedicalCenterActiveStaff,InternationalEyeInstitute,StLuke'sMedicalCenterGlobalCityVisitingOphthalmologist,AMCEyeCenter,AlabangMedicalCenter

    BarbaraLRoque,MDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanAssociationforPediatricOphthalmologyandStrabismus,AmericanSocietyofCataractandRefractiveSurgery,PhilippineAcademyofOphthalmology,PhilippineSocietyofCataractandRefractiveSurgery,andPhilippineSocietyofPediatricOphthalmolo

    Disclosure:Nothingtodisclose.

    ElisabettaMiserocchi,MDFellowinImmunologyandUveitisService,DepartmentofOphthalmology,HarvardMedicalSchool

    Disclosure:Nothingtodisclose.

    CStephenFoster,MD,FACS,FACR,FAAOClinicalProfessorofOphthalmology,HarvardMedicalSchoolConsultingStaff,DepartmentofOphthalmology,MassachusettsEyeandEarInfirmaryFounderandPresident,OcularImmunologyandUveitisFoundation,MassachusettsEyeResearchandSurgeryInstitution

    CStephenFoster,MD,FACS,FACR,FAAOisamemberofthefollowingmedicalsocieties:AlphaOmegaAlpha,AmericanAcademyofOphthalmology,AmericanAssociationofImmunologists,AmericanCollegeofRheumatology,AmericanCollegeofSurgeons,AmericanFederationforClinicalResearch,AmericanMedicalAssociation,AmericanSocietyforMicrobiology,AmericanUveitisSociety,AssociationforResearchinVisionandOphthalmology,MassachusettsMedicalSociety,RoyalSocietyofMedicine,andSigmaXi

    Disclosure:Nothingtodisclose.

    SpecialtyEditorBoardAndrewADahl,MDDirectorofOphthalmologyTeaching,MidHudsonFamilyPracticeInstitute,TheInstituteforFamilyHealthAssistantProfessorofSurgery(Ophthalmology),NewYorkCollegeofMedicine

    AndrewADahl,MDisamemberofthefollowingmedicalsocieties:AlphaOmegaAlpha,AmericanAcademyofOphthalmology,AmericanCollegeofSurgeons,AmericanMedicalAssociation,AmericanSocietyofCataractandRefractiveSurgery,andWildernessMedicalSociety

    Disclosure:Nothingtodisclose.

    SimonKLaw,MD,PharmDClinicalProfessorofHealthSciences,DepartmentofOphthalmology,JulesSteinEyeInstitute,UniversityofCalifornia,LosAngeles,DavidGeffenSchoolofMedicine

    SimonKLaw,MD,PharmDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanGlaucomaSociety,andAssociationforResearchinVisionandOphthalmology

    Disclosure:Nothingtodisclose.

    RChristopherWalton,MDProfessor,DirectorofUveitisandOcularInflammatoryDiseaseService,DepartmentofOphthalmology,UniversityofTennesseeCollegeofMedicine

    RChristopherWalton,MDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanCollegeofHealthcareExecutives,AmericanUveitisSociety,AssociationforResearch

  • 3/25/2015 JuvenileIdiopathicArthritisUveitis

    http://emedicine.medscape.com/article/1209891overview 3/5

    inVisionandOphthalmology,andRetinaSociety

    Disclosure:Nothingtodisclose.

    LanceLBrown,OD,MDOphthalmologist,AffiliatedWithFreemanHospitalandStJohn'sHospital,RegionalEyeCenter,Joplin,Missouri

    Disclosure:Nothingtodisclose.

    ChiefEditorHamptonRoySr,MDAssociateClinicalProfessor,DepartmentofOphthalmology,UniversityofArkansasforMedicalSciences

    HamptonRoySr,MDisamemberofthefollowingmedicalsocieties:AmericanAcademyofOphthalmology,AmericanCollegeofSurgeons,andPanAmericanAssociationofOphthalmology

    Disclosure:Nothingtodisclose.

    AdditionalContributorsTheauthorsandeditorsofMedscapeReferencegratefullyacknowledgetheassistanceofRyanIHuffman,MD,withtheliteraturereviewandreferencingforthisarticle.

    References

    1. NguyenQD,FosterCS.Savingthevisionofchildrenwithjuvenilerheumatoidarthritisassociateduveitis.JAMA.Oct71998280(13):11334.[Medline].

    2. PivnsaloHietanenT,TuominenJ,SaariKM.Uveitisinchildren:populationbasedstudyinFinland.ActaOphthalmolScand.Feb200078(1):848.[Medline].

    3. BooneMI,MooreTL,CruzOA.Screeningforuveitisinjuvenilerheumatoidarthritis.JPediatrOphthalmolStrabismus.JanFeb199835(1):413.[Medline].

    4. KotaniemiK,KaipiainenSeppanenO,SavolainenA,etal.Apopulationbasedstudyonuveitisinjuvenilerheumatoidarthritis.ClinExpRheumatol.JanFeb199917(1):11922.[Medline].

    5. MallesonP.Prevalenceandoutcomeofuveitisinaregionalcohortofpatientswithjuvenilerheumatoidarthritis.JRheumatol.Jun199825(6):1242.[Medline].

    6. KesenMR,SetlurV,GoldsteinDA.Juvenileidiopathicarthritisrelateduveitis.IntOphthalmolClin.Summer200848(3):2138.[Medline].

    7. WrightT,CronRQ.PediatricrheumatologyfortheadultrheumatologistII:uveitisinjuvenileidiopathicarthritis.JClinRheumatol.Aug200713(4):20510.[Medline].

    8. KanskiJJ.Anterioruveitisinjuvenilerheumatoidarthritis.ArchOphthalmol.Oct197795(10):17947.[Medline].

    9. GallagherKT,BernsteinB.Juvenilerheumatoidarthritis.CurrOpinRheumatol.Sep199911(5):3726.[Medline].

    10. KotaniemiK.Lateonsetuveitisinjuveniletypechronicpolyarthritiscontrolledwithprednisolone,cyclosporinAandmethotrexate.ClinExpRheumatol.JulAug199816(4):46971.[Medline].

    11. DonnRP,FarhanAJ,BarrettJH,etal.Absenceofassociationbetweeninterleukin1alphaandoligoarticularjuvenilechronicarthritisinUKpatients.Rheumatology(Oxford).Feb199938(2):1715.[Medline].

    12. ReiningaJK,LosLI,WulffraatNM,etal.Theevaluationofuveitisinjuvenileidiopathicarthritis(JIA)patients:arecurrentophthalmologicscreeningguidelinesadequate?.ClinExpRheumatol.MarApr200826(2):36772.[Medline].

    13. YenJH,TsaiWC,TsaiJJ,etal.HLADMAandHLADMBgenotypinginpatientswithrheumaticdiseases.KaohsiungJMedSci.May199915(5):2637.[Medline].

    14. CassidyJT.Medicalmanagementofchildrenwithjuvenilerheumatoidarthritis.Drugs.Nov199958(5):83150.[Medline].

    15. CeislerEJ,FosterCS.Juvenilerheumatoidarthritisanduveitis:minimizingtheblindingcomplications.IntOphthalmolClin.Winter199636(1):91107.[Medline].

    16. HemadyRK,BaerJC,FosterCS.Immunosuppressivedrugsinthemanagementofprogressive,corticosteroidresistantuveitisassociatedwithjuvenilerheumatoidarthritis.IntOphthalmolClin.Winter199232(1):24152.[Medline].

    17. YuEN,MeniconiME,TufailF,etal.Outcomesoftreatmentwithimmunomodulatorytherapyinpatientswithcorticosteroidresistantjuvenileidiopathicarthritisassociatedchroniciridocyclitis.OculImmunolInflamm.SepOct200513(5):35360.[Medline].

    18. KilmartinDJ,ForresterJV,DickAD.CyclosporinAtherapyinrefractorynoninfectiouschildhooduveitis.BrJOphthalmol.Jul199882(7):73742.[Medline].

    19. OkadaAA.Immunomodulatorytherapyforocularinflammatorydisease:abasicmanualandreviewoftheliterature.OculImmunolInflamm.SepOct200513(5):33551.[Medline].

    20. ShettyAK,ZganjarBE,EllisGSJr,etal.Lowdosemethotrexateinthetreatmentofseverejuvenilerheumatoidarthritisandsarcoidiritis.JPediatrOphthalmolStrabismus.MayJun199936(3):1258.[Medline].

    21. SingerNG,McCuneWJ.Updateonimmunosuppressivetherapy.CurrOpinRheumatol.May

  • 3/25/2015 JuvenileIdiopathicArthritisUveitis

    http://emedicine.medscape.com/article/1209891overview 4/5

    199810(3):16973.[Medline].

    22. WeissAH,WallaceCA,SherryDD.Methotrexateforresistantchronicuveitisinchildrenwithjuvenilerheumatoidarthritis.JPediatr.Aug1998133(2):2668.[Medline].

    23. ImrieFR,DickAD.Biologicsinthetreatmentofuveitis.CurrOpinOphthalmol.Nov200718(6):4816.[Medline].

    24. TynjalaP,KotaniemiK,LindahlP,etal.Adalimumabinjuvenileidiopathicarthritisassociatedchronicanterioruveitis.Rheumatology(Oxford).Mar200847(3):33944.[Medline].

    25. HeiligenhausA,MingelsA,HeinzC,etal.Methotrexateforuveitisassociatedwithjuvenileidiopathicarthritis:valueandrequirementforadditionalantiinflammatorymedication.EurJOphthalmol.SepOct200717(5):7438.[Medline].

    26. IlowiteNT.Updateonbiologicsinjuvenileidiopathicarthritis.CurrOpinRheumatol.Sep200820(5):6138.[Medline].

    27. BenEzraD,CohenE.Cataractsurgeryinchildrenwithchronicuveitis.Ophthalmology.Jul2000107(7):125560.[Medline].

    28. HollandGN.Intraocularlensimplantationinpatientswithjuvenilerheumatoidarthritisassociateduveitis:anunresolvedmanagementissue.AmJOphthalmol.Aug1996122(2):2557.[Medline].

    29. AcevedoS,QuinonesK,RaoV,etal.Cataractsurgeryinchildrenwithjuvenileidiopathicarthritisassociateduveitis.IntOphthalmolClin.Spring200848(2):17.[Medline].

    30. SijssensKM,LosLI,RothovaA,SchellekensPA,vandeDoesP,StilmaJS.Longtermocularcomplicationsinaphakicversuspseudophakiceyesofchildrenwithjuvenileidiopathicarthritisassociateduveitis.BrJOphthalmol.Sep201094(9):11459.[Medline].

    31. DanaMR,MerayoLlovesJ,SchaumbergDA,etal.Visualoutcomesprognosticatorsinjuvenilerheumatoidarthritisassociateduveitis.Ophthalmology.Feb1997104(2):23644.[Medline].

    32. FoxGM,FlynnHWJr,DavisJL,etal.Causesofreducedvisualacuityonlongtermfollowupaftercataractextractioninpatientswithuveitisandjuvenilerheumatoidarthritis.AmJOphthalmol.Dec151992114(6):70814.[Medline].

    33. OzdalPC,ViannaRN,DeschnesJ.Visualoutcomeofjuvenilerheumatoidarthritisassociateduveitisinadults.OculImmunolInflamm.Feb200513(1):338.[Medline].

    34. GrayT,KanskiJ,LightmanS.Steroidresponsivediscneovascularisationinuveitisassociatedwithjuvenilechronicarthritis.BrJOphthalmol.Mar199882(3):3278.[Medline].

    35. DucosdeLahitteG,TerradaC,TranTH,etal.Maculopathyinuveitisofjuvenileidiopathicarthritis:anopticalcoherencetomographystudy.BrJOphthalmol.Jan200892(1):649.[Medline].

    36. WolfMD,LichterPR,RagsdaleCG.Prognosticfactorsintheuveitisofjuvenilerheumatoidarthritis.Ophthalmology.Oct198794(10):12428.[Medline].

    37. AggarwalA,MisraRN.JuvenilerheumatoidarthritisinIndiararityofantinuclearantibodyanduveitis.IndianJPediatr.MayJun199663(3):3014.[Medline].

    38. AkinciA,CakarN,UncuN,etal.Keratoconjunctivitissiccainjuvenilerheumatoidarthritis.Cornea.Sep200726(8):9414.[Medline].

    39. AnesiSD,FosterCS.Theimportanceofrecognizingjuvenileidiopathicarthritisassociateduveitisandpreventingblindnessfromit.ArthritisCareRes(Hoboken).Jan92012[Medline].

    40. AngelesHanS,YehS.Preventionandmanagementofcataractsinchildrenwithjuvenileidiopathicarthritisassociateduveitis.CurrRheumatolRep.Apr201214(2):1429.[Medline].

    41. AngelesHanST,GriffinKW,HarrisonMJ,LehmanTJ,LeongT,RobbRR,etal.Developmentofavisionrelatedqualityoflifeinstrumentforchildrenages818yearsforuseinjuvenileidiopathicarthritisassociateduveitis.ArthritisCareRes(Hoboken).Sep201163(9):125461.[Medline].[FullText].

    42. BaldassanoVFJr.Ocularmanifestationsofrheumaticdiseases.CurrOpinOphthalmol.Dec19989(6):858.[Medline].

    43. DollfusH.Eyeinvolvementinchildren'srheumaticdiseases.BaillieresClinRheumatol.May199812(2):30928.[Medline].

    44. GrajewskiRS,ZurekImhoffB,RoeselM,HeinzC,HeiligenhausA.FavourableoutcomeaftercataractsurgerywithIOLimplantationinuveitisassociatedwithjuvenileidiopathicarthritis.ActaOphthalmol.Feb112011[Medline].

    45. HeiligenhausA,FoeldvariI,EdelstenC,SmithJR,SaurenmannRK,BodaghiB,etal.Proposedoutcomemeasuresforprospectiveclinicaltrialsinjuvenileidiopathicarthritisassociateduveitis:Aconsensuseffortfromthemultinationalinterdisciplinaryworkinggroupforuveitisinchildhood(MIWGUC).ArthritisCareRes(Hoboken).Mar212012[Medline].

    46. HeiligenhausA,MichelsH,SchumacherC,KoppI,NeudorfU,NiehuesT,etal.Evidencebased,interdisciplinaryguidelinesforantiinflammatorytreatmentofuveitisassociatedwithjuvenileidiopathicarthritis.RheumatolInt.Nov152011[Medline].

    47. HeiligenhausA,MiserocchiE,HeinzC,GerloniV,KotaniemiK.TreatmentofsevereuveitisassociatedwithjuvenileidiopathicarthritiswithantiCD20monoclonalantibody(rituximab).Rheumatology(Oxford).Aug201150(8):13904.[Medline].

    48. HeinzC,SchumacherC,RoeselM,HeiligenhausA.Elevatedintraocularpressureinuveitisassociatedwithjuvenileidiopathicarthritisassociateduveitis,oftendetectedafterachievinginactivity.BrJ

  • 3/25/2015 JuvenileIdiopathicArthritisUveitis

    http://emedicine.medscape.com/article/1209891overview 5/5

    MedscapeReference2011WebMD,LLC

    Ophthalmol.Jan201296(1):1401.[Medline].

    49. HoeveM,KalininaAyusoV,SchalijDelfosNE,LosLI,RothovaA,deBoerJH.Theclinicalcourseofjuvenileidiopathicarthritisassociateduveitisinchildhoodandpuberty.BrJOphthalmol.Mar72012[Medline].

    50. KalininaAyusoV,vandeWinkelEL,RothovaA,deBoerJH.Relapserateofuveitispostmethotrexatetreatmentinjuvenileidiopathicarthritis.AmJOphthalmol.Feb2011151(2):21722.[Medline].

    51. KenawyN,ClearyG,MewarD,BeareN,ChandnaA,PearceI.Abatacept:apotentialtherapyinrefractorycasesofjuvenileidiopathicarthritisassociateduveitis.GraefesArchClinExpOphthalmol.Feb2011249(2):297300.[Medline].

    52. KotaniemiK,SilH,KautiainenH.Longtermefficacyofadalimumabinthetreatmentofuveitisassociatedwithjuvenileidiopathicarthritis.ClinOphthalmol.20115:14259.[Medline].[FullText].

    53. QianY,AcharyaNR.Juvenileidiopathicarthritisassociateduveitis.CurrOpinOphthalmol.Nov201021(6):46872.[Medline].[FullText].

    54. RabinovichCE.Treatmentofjuvenileidiopathicarthritisassociateduveitis:challengesandupdate.CurrOpinRheumatol.Sep201123(5):4326.[Medline].

    55. SinghS,SalariaM,KumarL,etal.ClinicoimmunologicalprofileofjuvenilerheumatoidarthritisatChandigarh.IndianPediatr.May199936(5):44954.[Medline].

    56. TappeinerC,HeinzC,RoeselM,HeiligenhausA.Elevatedlaserflarevaluescorrelatewithcomplicatedcourseofanterioruveitisinpatientswithjuvenileidiopathicarthritis.ActaOphthalmol.Sep201189(6):e5217.[Medline].